한글목차

베단타 바이오사이언스가 개발중인 VE303은 고위험군 CDI에 대한 경구용 박테리아 컨소시엄 후보물질로, 클로스트리듐 디피실 감염에 대한 집락형성 저항성을 가진 8가지 클론성 인간 상재균 균주에서 선택된 것입니다.

VE303은 클론성 박테리아 세포은행에서 생산되어 분말 형태의 표준화된 의약품을 얻을 수 있으므로 성분이 일정하지 않은 기증자의 대변에서 직접 조달하는 것에 의존할 필요가 없습니다. 이 제제는 장내 면역 관용을 유도하고 염증성 장 질환(IBD) 환자에게서 흔히 나타나는 장내 세균총의 이상을 회복하고 상피 장벽을 강화하도록 설계되었습니다.

앞으로 수년간 클로스트리듐 디피실 감염증 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것으로 예상됩니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, VE303의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 클로스트리듐 디피실 감염에 대한 다른 신흥 제품들은 VE303과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

주요 7개국의 VE303 시장에 대해 조사했으며, 시장의 개요와 2026-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 클로스트리듐 디피실 감염증에 대한 VE303의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 VE303 시장 평가

• 클로스트리듐 디피실 감염증에 대한 VE303의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국의 클로스트리듐 디피실 감염증에 대한 VE303의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"VE303 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VE303 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the VE303 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VE303 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VE303 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

VE303, being developed by Vedanta Biosciences, is an orally administered bacterial consortium candidate for high-risk CDI. VE303 consists of eight types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile.

VE303 is produced from clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing from the donor's fecal material of the inconsistent composition. It is designed to induce immune tolerance in the gut, reverse the gut microbiota abnormalities common in patients with inflammatory bowel disease (IBD), and strengthen the epithelial barrier.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VE303 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on VE303 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VE303 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VE303.
• The report contains forecasted sales of VE303 for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for VE303 in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VE303 Analytical Perspective by DelveInsight

In-depth VE303 Market Assessment

This report provides a detailed market assessment of VE303 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

VE303 Clinical Assessment

The report provides the clinical trials information of VE303 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VE303 dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to VE303 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VE303 in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of VE303 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VE303 in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of VE303?
• What is the clinical trial status of the study related to VE303 in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VE303 development?
• What are the key designations that have been granted to VE303 for clostridium difficile infection?
• What is the forecasted market scenario of VE303 for clostridium difficile infection?
• What are the forecasted sales of VE303 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to VE303 for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. VE303 Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VE303 Market Assessment

• 5.1. Market Outlook of VE303 in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VE303 in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VE303 in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of VE303 in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of VE303 in France for Clostridium difficile infection
  • 5.3.4. Market Size of VE303 in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of VE303 in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of VE303 in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of VE303 in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options